<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8800478</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1990</journal-id>
<journal-id journal-id-type="nlm-ta">Brain Behav Immun</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Behav. Immun.</journal-id>
<journal-title-group>
<journal-title>Brain, behavior, and immunity</journal-title>
</journal-title-group>
<issn pub-type="ppub">0889-1591</issn>
<issn pub-type="epub">1090-2139</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26883520</article-id>
<article-id pub-id-type="pmc">5531048</article-id>
<article-id pub-id-type="doi">10.1016/j.bbi.2016.02.014</article-id>
<article-id pub-id-type="manuscript">NIHMS881192</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>CX<sub>3</sub>CR1 ablation ameliorates motor and respiratory dysfunctions and improves survival of a Rett syndrome mouse model</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Horiuchi</surname>
<given-names>Makoto</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smith</surname>
<given-names>Lucas</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maezawa</surname>
<given-names>Izumi</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jin</surname>
<given-names>Lee-Way</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>a</label>Department of Pathology and Laboratory Medicine, 2805 50th Street, UC Davis Medical Center, Sacramento, CA 95817, United States</aff>
<aff id="A2">
<label>b</label>M.I.N.D. (Medical Investigation of Neurodevelopmental Disorders) Institute, 2805 50th Street, UC Davis Medical Center, Sacramento, CA 95817, United States</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author at: Dept. of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA 95817, United States. <email>lwjin@ucdavis.edu</email> (L.-W. Jin)</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>5</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>13</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>27</day>
<month>7</month>
<year>2017</year>
</pub-date>
<volume>60</volume>
<fpage>106</fpage>
<lpage>116</lpage>
<!--elocation-id from pubmed: 10.1016/j.bbi.2016.02.014-->
<abstract>
<p id="P1">Rett syndrome (RTT) is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding MeCP2, an epigenetic modulator that binds the methyl CpG dinucleotide in target genes to regulate transcription. Previously we and others reported a role of microglia in the pathophysiology of RTT. Because microglia in the <italic>Mecp2</italic> knockout (<italic>Mecp2KO</italic>) mouse model of RTT over-produce neurotoxic mediators glutamate and reactive oxygen species, we hypothesize that blocking neuron–microglia interaction by ablation of CX<sub>3</sub>CR1, a chemokine receptor expressed in microglia/myeloid cells mediating such interaction by pairing with its neuronal ligand CX<sub>3</sub>CL1, would ameliorate the RTT-like phenotype in <italic>Mecp2KO</italic> mice. Here we report that CX<sub>3</sub>CR1 ablation prolonged the lifespan of <italic>Mecp2KO</italic> mice from a median survival of 54.5–74 days, and significantly improved the body weight gain, symptomatic scores, major respiratory parameters, and motor coordination and performance. CX<sub>3</sub>CR1 ablation rectified previously identified histological abnormalities in the <italic>Mecp2KO</italic> brain such as neuronal soma size in hippocampal CA2, and the number, soma size, and process complexity of microglia. Moreover, CX<sub>3</sub>CR1 ablation enhanced the neurotrophic action of microglia in <italic>Mecp2KO</italic> mice by producing higher amount of insulin-like growth factor 1. Our data support a role of myeloid cells/microglia in RTT and suggest a novel therapeutic approach for RTT by targeting CX<sub>3</sub>CR1 with specific antagonists or genetic downregulation.</p>
</abstract>
<kwd-group>
<kwd>ett syndrome</kwd>
<kwd>MeCP2</kwd>
<kwd>Microglia</kwd>
<kwd>CX<sub>3</sub>CR1</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>